PPT Slide
Alfimeprase: Near-term Product Opportunity
- World class partner, Amgen
- Novel acting thrombolytic (clot dissolver)
- Compelling pre-clinical data—faster & more consistent clot lysis
- Currently in two Phase 2 trials
- Targeting multiple, local delivery, vascular indications
- Granted orphan drug status for peripheral arterial occlusion (PAO)
- Market large and underserved
- Strong intellectual property protection